focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jul 2016 15:14

RNS Number : 0356D
GW Pharmaceuticals PLC
01 July 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

GW PHARMACEUTICALS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

ü

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

FMR LLC

4. Full name of shareholder(s)  (if different from 3.):iv

See Section 9

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

29 June 2016

6. Date on which issuer notified:

1 July 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Indirect

Direct xi

Indirect xii

Direct

Indirect

 

GB0030544687

13,772,976

13,772,976

13,240,176

13,240,176

5.03%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

Right of Recall

5,956,800

2.27%

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

19,196,976

7.30%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Controlled Undertaking

Common Stock

Qualifying Financial Instruments

Total Holdings

Fidelity Institutional Asset Management Trust Company

0.04

0

0.04

FMR CO., INC

4.99

2.27

7.26

Grand Total

5.03

2.27

7.30

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will acquire:

12. Date on which proxy holder will acquire voting rights:

13. Additional information:

Threshold crossing by a controlled undertaking

14. Contact name:

Sally-Ann Hatton

15. Contact telephone number:

 

fil-regreporting@fil.com, 01737 837148

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEALXFEFAKEFF
Date   Source Headline
25th Nov 20097:02 amRNSPatient Recruitment Completed for Sativex Study
25th Nov 20097:00 amRNSFinal Results
23rd Nov 20097:00 amRNSPositive Sativex Results in Cancer Pain
4th Nov 200912:15 pmRNSNotice of Results
30th Oct 20094:43 pmRNSBlocklisting Interim Review
30th Oct 20093:41 pmRNSTotal Voting Rights
17th Sep 20094:40 pmRNSSecond Price Monitoring Extn
17th Sep 20094:35 pmRNSPrice Monitoring Extension
17th Sep 20097:00 amRNSUpdate on cannabinoid pipeline
14th Sep 20097:00 amRNSResults from two clinical studies of Savitex(R)
10th Sep 20097:00 amRNSRodman and Renshaw Conference
18th Aug 20094:23 pmRNSHolding(s) in Company
18th Aug 20094:18 pmRNSTotal Voting Rights
6th Aug 20097:00 amRNSRe Agreement
28th Jul 200911:10 amRNSDirector/PDMR Shareholding
16th Jul 20097:00 amRNSManufacturing Licence Received for Sativex
26th Jun 20098:41 amRNSDirector/PDMR Shareholding
24th Jun 20099:19 amRNSDirector/PDMR Shareholding
16th Jun 20097:00 amRNSGW Expands Cannabinoid Research
15th Jun 20095:46 pmRNSDirector/PDMR Shareholding
2nd Jun 20097:00 amRNSHolding(s) in Company
1st Jun 20094:12 pmRNSNotification of Interests of Directors
21st May 20094:00 pmRNSDirector/PDMR Shareholding
20th May 20097:01 amRNSGW Files Sativex? Regulatory Submission
20th May 20097:00 amRNSInterim Results
20th Apr 20093:20 pmRNSNotice of Results
1st Apr 20097:00 amRNS?8m Milestone Payment from Almirall
31st Mar 20097:00 amRNSBlocklisting Interim Review
31st Mar 20097:00 amRNSTotal Voting Rights
30th Mar 200910:11 amRNSDirector/PDMR Shareholding
27th Mar 20094:51 pmRNSDirector/PDMR Shareholding
13th Mar 20099:34 amRNSNotification of Interests of Directors
11th Mar 20091:12 pmRNSPositive Outcome of Sativex Phase III MS Study
2nd Mar 20095:38 pmRNSDirector/PDMR Shareholding
24th Feb 20097:00 amRNSClinical Trial Update
16th Jan 20095:27 pmRNSDirector/PDMR Shareholding
14th Jan 20092:05 pmRNSResult of AGM
2nd Dec 20085:50 pmRNSDirector/PDMR Shareholding
18th Nov 20087:00 amRNSFinal Results
24th Oct 20084:47 pmRNSSecond Price Monitoring Extn
24th Oct 20084:37 pmRNSPrice Monitoring Extension
22nd Oct 200811:00 amRNSNotice of Results
10th Oct 20084:42 pmRNSPrice Monitoring Extension
1st Oct 20087:00 amRNSTrial Completes Recruitment
8th Sep 20087:00 amRNSResearch Update
18th Jul 20084:38 pmRNSDirector/PDMR Shareholding
24th Jun 20083:36 pmRNSBlocklisting Interim Review
24th Jun 20083:32 pmRNSBlocklisting Interim Review
24th Jun 20083:27 pmRNSBlocklisting Interim Review
24th Jun 20083:22 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.